Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1158/1078-0432.CCR-20-1657

http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-20-1657
suck pdf from google scholar
32540850!ä!32540850

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32540850      Clin+Cancer+Res 2020 ; 26 (16): 4201-4205
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era #MMPMID32540850
  • Maio M; Hamid O; Larkin J; Covre A; Altomonte M; Calabro L; Vardhana SA; Robert C; Ibrahim R; Anichini A; Wolchok JD; Giacomo AMD
  • Clin Cancer Res 2020[Aug]; 26 (16): 4201-4205 PMID32540850show ga
  • The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
  • |Antineoplastic Agents, Immunological/pharmacology/*therapeutic use[MESH]
  • |B7-H1 Antigen/antagonists & inhibitors/immunology[MESH]
  • |Betacoronavirus/*immunology[MESH]
  • |COVID-19[MESH]
  • |CTLA-4 Antigen/antagonists & inhibitors/immunology[MESH]
  • |Clinical Decision-Making[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Coronavirus Infections/epidemiology/*immunology/prevention & control/virology[MESH]
  • |Humans[MESH]
  • |Neoplasms/*drug therapy/immunology[MESH]
  • |Pandemics/prevention & control[MESH]
  • |Pneumonia, Viral/epidemiology/*immunology/prevention & control/virology[MESH]
  • |Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box